Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


SCCA Clinical Studies: Lung Cancer

 

MPDL3280A for PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (UW13020)
A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

Investigator: Laura Q.M. Chow, MD;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01846416

ABRAXANE® (Nab-Paclitaxel) for Advanced NSCLC (7755)
A Phase II Study of Weekly ABRAXANE® (Nab-Paclitaxel) for Patients with Advanced NSCLC with EGFR Mutations Following Front-Line Therapy with EGFR Tyrosine Kinase Inhibitors

Investigator: Christina Baik;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT01620190

BMS-936558 versus Docetaxel for Non-squamous Non-small Cell Lung Cancer (UW12017)
An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Investigator: Laura Chow, MD;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT01673867

BMS-936558 Versus Docetaxel for Squamous Non-small Cell Lung Cancer (UW12021)
An Open-Label Randomized Phase III Trial of BMS-936558 Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

Investigator: Laura Chow, MD;   Conditions: Squamous Cell Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01642004

Radiation Therapy + Cisplatin & Etoposide for Inoperable NSCLC (7506)
A Phase I dose-intensification study using radiation therapy and concurrent cisplatin and etoposide for patients with inoperable non-small cell lung cancer

Investigator: Shilpen Patel, MD;   Conditions: Lung Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT01411098

MDX-1105 for Advanced or Recurrent Cancer (UW08038)
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors

Investigator: Scott S. Tykodi, MD, PhD;   Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer;    Status: Recruiting;   Study ID: NCT00729664

LDK378 for Tumors with ALK Mutation (UW10038)
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

Investigator: Laura Chow, MD;   Conditions: Tumors Characterized by Genetic Abnormalities of ALK;    Status: Closed;   Study ID: NCT01283516

SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy (8180)
Pulmonary Functional Imaging for Radiation Treatment Planning for Lung Cancer

Investigator: Jing Zeng;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT01982123

Early Diagnosis of Pulmonary Nodules (2658)
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier

Investigator: David Madtes, MD;   Conditions: Precancerous Conditions;    Status: Recruiting;   Study ID: NCT01752114

Onartuzumab (MetMAb) for Squamous Non-Small Cell Lung Cancer (UW11048)
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Gemcitabine + Cisplatin or Carboplatin as First-line Treatment for Patients With Stage IIIb or IV Squamous Non-small Cell Lung Cancer (NSCLC)

Investigator: Keith D. Eaton, MD;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01519804

Safety and Tolerability of Nivolumab (BMS-936558) for Non-small Cell Lung Cancer (UW11037)
A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab maintenance, Erlotinib, Ipilimumab or monotherapy in First line or in Switch Maintenance in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)

Investigator: Laura Q.M. Chow, MD;   Conditions: Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01454102

Ramucirumab + Docetaxel for Malignant Solid Tumors
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Docetaxel in Patients With Advanced Malignant Solid Tumors

Investigator: Laura Q.M. Chow, MD;   Conditions: Malignant Solid Tumor;    Status: Closed;   Study ID: NCT01567163

Ramucirumab + Paclitaxel for Malignant Solid Tumors
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors

Investigator: Laura Q.M. Chow, MD;   Conditions: Malignant Solid Tumor;    Status: Closed;   Study ID: NCT01515306

Nivolumab (anti-PD1)/IL-21 Combination in the Treatment of Solid Tumors
A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms by Site;    Status: Closed;   Study ID: NCT01629758

AT13387 in Combination with Crizotinib for NSCLC (UW12024)
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)

Investigator: Renato G. Martins, MD, MPH;   Conditions: Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01712217

BRAF Kinase Inhibitor GSK2118436 for Advanced NSCLC and BRAF Mutations (UW12020)
A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations

Investigator: Renato G. Martins, MD;   Conditions: Advanced Non-small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01336634

LDK378 for Crizotinib naïve Patients With ALK-activated NSCLC (UW12039)
A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Investigator: Renato G. Martins, MD;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT01685138

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC (UW13035)
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity

Investigator: Laura Q.M. Chow, MD;   Conditions: Non-small Cell Lung Cancer (NSCLC);    Status: Recruiting;   Study ID: NCT01947608

Alisertib (MLN8237) in Combination With Paclitaxel for Small Cell Lung Cancer
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC).

Investigator: Christina S. Baik, MD;   Conditions: Small Cell Lung Cancer;    Status: Pending;   Study ID: NCT02038647

LY2875358 + Erlotinib for Non-Small-Cell Lung Cancer (I4C-MC-JTBC)
A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib

Investigator: ;   Conditions: Lung Cancer;    Status: Recruiting;   Study ID: NCT01900652

MEDI4736 (Anti PD-L1) w/ Gefitinib for Non-Small Cell Lung Cancer
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Gefitinib in Combination With MEDI4736 (Anti PD-L1) in Subjects With Non-Small Cell Lung Cancer(NSCLC)

Investigator: Laura Chow, MD;   Conditions: Non-Small Cell Lung Cancer;    Status: Recruiting;   Study ID: NCT02088112